Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor-κB in human osteoarthritis chondrocytes

Rheumatology

Volumn 50, Issue 5, 2011, Pages 838-851

  Rasheed, Zafar ^a   Akhtar, Nahid ^a   Haqqi, Tariq M ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Interleukin 6; Interleukin 8; Mitogen activated protein kinases; Nuclear factor B; Osteoarthritis; Receptor for advanced glycation end product

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN INHIBITOR; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTIBODIES; CELLS, CULTURED; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MAP KINASE KINASE 4; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OSTEOARTHRITIS; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; S100 PROTEINS; SIGNAL TRANSDUCTION;

EID: 79955160610     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq380     Document Type: Article

References (54)

1. Felson DT, Lawrence RC, Dieppe PA et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635-46.
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350:503-8.
3. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention [review]. Arthritis Rheum 1998;41:1343-55.
4. Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999;42: 17-24.
5. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J Biol Chem 1989;264:21597-602.
6. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-8.
7. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. Ageing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003;15:616-22.
8. Uchiyama A, Ohishi T, Takahashi M et al. Fluorophores from aging human articular cartilage. J Biochem 1991;110: 714-8.
9. Takahashi M, Kushida K, Ohishi T et al. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994;37:724-8.
10. Verzijl N, DeGroot J, Oldehinkel E e t al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000;350:381-7.
11. Bank RA, Bayliss MT, Lafeber FPJG, Maroudas A, TeKoppele JM. Ageing and zonal variation in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic glycation affects biomechanical properties of cartilage. Biochem J 1998;330:345-51.
12. Bailey AJ, Sims TJ, Avery NC, Miles CA. Chemistry of collagen cross-links: glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 1993;296:489-96.
13. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996;39:946-51.
14. Chen AC, Temple MM, Ng DM et al. Induction of advanced glycation end products and alterations of the tensile properties of articular cartilage. Arthritis Rheum 2002;46:3212-7.
15. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97: 889-901.
16. Loeser RF, Yammani RR, Carlson CS et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005;52:2376-85.
17. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006;54:2901-11.
18. Nah SS, Choi IY, Yoo B, Kim YG, Moon HB, Lee CK. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett 2007;581: 1928-32.
19. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003;33:155-67.
20. Fermor B, Weinberg JB, Pisetsky DS, Misukonis MA, Fink C, Guilak F. Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. Osteoarthritis Cartilage 2002;10:792-8.
21. Nah SS, Choi IY, Lee CK et al. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology 2008;47:425-31.
22. Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: advances and limitations. Immunity 2008;28:440-4.
23. Koch AE, Kunkel SL, Burrows JC et al. Synovial tissue macrophages as a source of the chemotactic cytokine IL-8. J Immunol 1991;147:2187-95.
24. Kitahara K, Kusunoki N, Kakiuchi T, Suguro T, Kawai S. Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2009;378:218-23.
25. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42.
26. Akira S, Taga T, Kishimoto T. Interleukin 6 in biology and medicine. Adv Immunol 1993;54:1-78.
27. Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol 2005;28:177-86.
28. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum 1988;31: 784-8.
29. Aherne CM, McMorrow J, Kane D, FitzGerald O, Mix KS, Murphy EP. Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. Mol Immunol 2009;46:3345-57.
30. Choi HM, Oh DH, Bang JS, Yang HI, Yoo MC, Kim KS. Differential effect of IL-1beta and TNF-alpha on the production of IL-6, IL-8 and PGE(2) in fibroblast-like synoviocytes and THP-1 macrophages. Rheumatol Int 2010; 30:1025-33.
31. Sakao K, Takahashi KA, Arai Y et al. Osteoblasts derived from osteophytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis. J Bone Miner Metab 2009;27:412-23.
32. Kaneko S, Satoh T, Chiba J, Ju C, Inove K, Kagawa J. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000;6:71-9.
33. Alonzi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8.
34. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6-receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
35. Matsukawa A, Yoshimura T, Maeda T, Ohkawara S, Takagi K, Yoshinaga M. Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. J Immunol 1995;154: 5418-25.
36. Rasheed Z, Akhtar N, Anbazhagan AN, Ramamurthy S, Shukla M, Haqqi TM. Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI-induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP kinases and NF-κB in human KU812 cells. J Inflamm 2009;6:1.
37. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappa B. Arthritis Rheum 2002;46:2079-86.
38. Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004;308:767-73.
39. Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum 2010;62:1361-71.
40. Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss F, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end products-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009;11:R71.
41. Valencia JV, Weldon SC, Quinn D et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004;324:68-78.
42. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29: e45.
43. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. Ageing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003;15:616-22.
44. DeGroot J, Verzijl N, Wenting-van Wijk MJ et al. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum 2004;50:1207-15.
45. Steenvoorden MM, Huizinga TW, Verzijl N et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006;54:253-63.
46. McCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91: 2470-8.
47. Waine H, Nevinny D, Rosenthal J, Joffe IB. Association of osteoarthritis and diabetes mellitus. Tufts Folia Med 1961; 7:13-9.
48. Campbell WL, Feldman F. Bone and soft tissue abnormalities of the upper extremity in diabetes mellitus. Am J Roentgenol Radium Ther Nucl Med 1975;124:7-16.
49. Bagge E, Bjelle A, Eden S, Svanborg A. Factors associated with radiographic osteoarthritis: results from the population study 70-year-old people in Göteborg. J Rheumatol 1991;18:1218-22.
50. Steenvoorden MM, Huizinga TW, Verzijl N et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006;54:253-63.
51. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003;550:107-13.
52. Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001;50: 1495-504.
53. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18:2195-224.
54. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8: 49-62.